Posts by: Patricia Silva PhD

Patricia Silva PhD

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

April 11, 2017April 11, 2017

Mast’s New Therapy for Chronic Lung Infection Enters Phase 1/2 Trial

News

AIR001, a new treatment for Pseudomonas aeruginosa infection in patients with lung diseases such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis, will be evaluated in an open-label Phase 1/2 clinical trial, according ... Read more

April 4, 2017April 4, 2017

Removing Antibodies from Bloodstream May Reduce Chronic Lung Infections in Bronchiectasis

News

Removing particular antibodies from the bloodstream of patients with bronchiectasis may reduce the negative effects of chronic bacterial infections, the need for days spent in the hospital, and the use ... Read more

March 7, 2017March 7, 2017

International Biophysics’ AffloVest Device Fuels Company’s Growth

News

Austin-based International Biophysics Corporation recently announced that sales of its AffloVest device in the U.S. helped fuel revenue growth of 34% in 2016, in addition to the expansion of its global sales of ... Read more

January 17, 2017January 17, 2017

Aerobika Device Shows Promise for Non-CF Bronchiectasis Patients

News

Recent research shows that non-cystic fibrosis (CF) bronchiectasis patients responded well to airway maintenance therapy using Aerobika, a drug-free device developed by Monaghan Medical. The study reporting the findings, “Non-Cystic Fibrosis ... Read more

January 10, 2017January 10, 2017

Aerobika Device Shows Promise in Treating Bronchiectasis, COPD Exacerbations

News

Trudell Medical International recently announced the results from a study assessing the response to airway maintenance therapy using the Aerobika device in patients with non-cystic fibrosis bronchiectasis. The results support the ... Read more

December 15, 2016December 15, 2016

Adults with Bronchiectasis at Higher Risk of Depression and Anxiety, Study Shows

News

Like many chronic lung disease patients, those with non-cystic fibrosis bronchiectasis are also at a higher risk of depression and anxiety, according to recent research. The study, “Factors related to depression and anxiety in ... Read more

September 27, 2016September 27, 2016

Last Patient Dosed in Phase 3 Trials of Pulmaquin for Non-Cystic Fibrosis Bronchiectasis

News

Aradigm reported that the final patient has completed the last dose appointment in the ORBIT-3 and ORBIT-4 Phase 3 clinical trials assessing Pulmaquin for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE) in ... Read more

June 21, 2016June 21, 2016

AffloVest Receives European CE Mark, and Approval in Canada, Australia

News

International Biophysics Corp., the company that developed, manufactures, and commercialize the AffloVest, recently received CE mark (CE stands for Conformité Européne, which literally means European Conformity), as well as Health Canada and ... Read more

May 31, 2016May 31, 2016

New Bronchiectasis Care Center Opens at UNC Chapel Hill

News

A new center dedicated to the treatment and care of bronchiectasis and related mycobacterial infection, is open at the UNC Pulmonary Specialty Clinic at Meadowmont, in Chapel Hill, N.C. The UNC Center for Bronchiectasis ... Read more

May 17, 2016May 17, 2016

Aradigm Presents Data on Inhaled Therapies for Bronchiectasis and Other Lung Infections at ATS 2016

News

Aradigm Corporation presented data from clinical trials assessing the drug, Pulmaquin, in people with non-cystic fibrosis bronchiectasis (NCFBE) and chronic Pseudomonas aeruginosa infections, and case studies of another drug, Lipoquin, to possibly prevent non-tuberculous mycobacteria formation in the ... Read more